SY-104 is under clinical development by Syena and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SY-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SY-104 overview

SY-104 is under development for the treatment of sarcoma and multiple myeloma. It comprises of allogeneic cord blood-derived natural killer cells (NK cells) which are genetically engineered to express T cell receptors (TCRs) targeting cells expressing cancer/testis antigen 1 (NY-ESO-1). It is being developed based on T cell receptor natural killer (TCR NK) platform.

Syena overview

Syena, is a product of Replay Holdings LLC, is engaged in the development and treatment of cancer cells with a compelling target for cancer immunotherapy. The company is headquartered in San Diego, California, the US.

For a complete picture of SY-104’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.